Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiments
- 173 Downloads
Enzastaurin (LY317615.HCl) is an antiproliferative agent targeted specifically against PKC-β. We have investigated the antitumoral effects of Enzastaurin against human cancer cell lines and freshly explanted human tumor tissue. Ten human cancer cell lines (NSCLC, colon, and thyroid) and human tumor specimens from 72 patients were used for in vitro studies in a cloning assay (HTCA). Cell lines and primary tumor cells were exposed to Enzastaurin for either 1 h or 7 days, or for 1 h or 21 days. At clinically achievable concentrations of Enzastaurin, inhibition of cell growth was observed for lung, colorectal, and thyroid cancer cell lines in a concentration dependent manner. Patient specimens exposed 1 h or 21 days to 1,400 nM Enzastaurin demonstrated inhibition rates of 24 and 32%, respectively. Marked inhibitory effects were observed in breast, thyroid, head/neck, non-small cell lung cancer, pancreatic cancer, and melanoma. In addition to its established antiangiogenic effects, Enzastaurin has direct antitumor activity against established human cancer cell lines and primary tumor specimens. This warrants further clinical development in tumors which have been identified to be potentially sensitive to Enzastaurin.
KeywordsEnzastaurin Human tumor cloning system
We are thankful to Eli Lilly & Company, Indianapolis, IN, USA, for support of this work.
- 7.Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL (1996) Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98(9):2018–2026PubMedCrossRefGoogle Scholar
- 12.Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D (2005) The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65(16):1–9CrossRefGoogle Scholar
- 13.Carducchi MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS (2006) Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24:4092–4099CrossRefGoogle Scholar
- 15.Fine HA, Kim L, Royce C, Mitchell S, Duic JP, Albert P, Musib L, Thornton D (2004) A phase II trial of LY317615 in patients with recurrent high grade gliomas. J Clin Oncol ASCO Annual Meeting Proceedings (Post meeting edition) 22(14S, July 15 Supplement):1511Google Scholar
- 16.Rademaker-Lakhai JM, Beereport L, Witteven EO, Radema SA, Visseren-Grul CM, Musib LC, van Hal G, Beijnen JH, Schellens JHM, Voest EE (2004) Phase I and pharmacologic study of Enzastaurin HCl, gemcitabine and cisplatin. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting-Edition) 22(14S, July 15 Supplement):3129Google Scholar
- 17.Vogel M, Hilsenbeck SG, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, Fellbaum C, Aapro MS, Bissery MC, Rastetter J, Hanauske A-R (1993) Preclinical activity of taxotere (RP56976, NSC628503) against freshly explanted clonogenic human tumor cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer 29A(14):2009–2014PubMedCrossRefGoogle Scholar
- 19.Hanauske A-R, Hilsenbeck SG, von Hoff DD (2004) Human tumor screening. In: Teicher BA, Andrews PA (eds) Cancer drug discovery and development: anticancer drug development guide: preclinical screenings, clinical trials, and approval, 2nd edn. Humana Press, Totowa, NJ, pp 63–76Google Scholar
- 20.Hanauske A-R, Hilsenbeck SG, von Hoff DD (1996) The human tumor cloning assay. In: Schilsky RL, Milano GA, Ratain MJ (eds) Principles of antineoplastic drug development and pharmacology. Marcel Dekker, New York, pp 15–27Google Scholar
- 23.Krejci P, Masri B, Salazar L, Farrington-Rock C, Prats H, Thompson LN, Wilcox WR (2006) Bisindolylamide I suppresses fibroblast growth factor-mediated activation of Erk MAP Kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J Biol Chem 282(5):2929–2936PubMedCrossRefGoogle Scholar
- 24.Uht RM, Amos S, Martin PM, Riggan AE, Hussaini IM (2006) The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene December 4 (epub)Google Scholar